Diletta Overi1, Guido Carpino2, Laura Cristoferi3,4, Paolo Onori1, Lindsey Kennedy5,6, Heather Francis5,6, Nicola Zucchini3,4, Cristina Rigamonti7, Mauro Viganò8, Annarosa Floreani9,10, Daphne D'Amato3, Alessio Gerussi3,4, Rosanna Venere11, Gianfranco Alpini5,6, Shannon Glaser12, Domenico Alvaro11, Pietro Invernizzi3,4, Eugenio Gaudio1, Vincenzo Cardinale13, Marco Carbone3,4. 1. Department of Anatomical, Histological, Forensic Medicine and Orthopedic Sciences, Sapienza University of Rome, Rome, Italy. 2. Department of Movement, Human and Health Sciences, Division of Health Sciences, University of Rome 'Foro Italico', Rome, Italy. 3. Division of Gastroenterology, Center for Autoimmune Liver Diseases, Department of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy. 4. European Reference Network on Hepatological Diseases (ERN RARE-LIVER), San Gerardo Hospital, Monza, Italy. 5. Hepatology and Gastroenterology, Medicine, Indiana University School of Medicine, Indianapolis, IN, USA. 6. Richard L. Roudebush VA Medical Center, Indianapolis, IN, USA. 7. Department of Translational Medicine, Università degli Studi del Piemonte Orientale 'A. Avogadro', Novara, Italy. 8. Division of Hepatology, Ospedale San Giuseppe, University of Milan, Milan, Italy. 9. Studiosa Senior, University of Padua, Padua, Italy. 10. Scientific Consultant, IRCCS Negrar, Verona, Italy. 11. Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy. 12. Department of Medical Physiology, Texas A&M University College of Medicine, Bryan, TX, USA. 13. Department of Medico-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Latina, Italy.
Abstract
Background & Aims: Primary biliary cholangitis (PBC) is a chronic cholangiopathy characterised by immuno-mediated injury of interlobular bile ducts leading to intrahepatic cholestasis and progressive liver fibrosis. PBC histology is characterised by portal inflammation, progressive fibrosis, ductopenia, and the appearance of the so-called ductular reaction. The aim of the present study was to investigate the pathogenetic relevance of ductular reaction in PBC. Methods: Liver biopsies were collected from naïve people with PBC (N = 87). Clinical-serological parameters were obtained at diagnosis and after 1 year of ursodeoxycholic acid (UDCA) treatment. Histological staging was performed on all slides according to multiple scoring systems and criteria for PBC. Liver samples were obtained from Mdr2 -/- mice treated with or without UDCA. Samples were processed for histology, immunohistochemistry, and immunofluorescence. Results: Ductular reaction in people with PBC correlated with the disease stage and liver fibrosis, but not with disease activity; an extensive ductular reaction correlated with serum alkaline phosphatase levels at diagnosis, response to UDCA, and individuals' estimated survival, independently from other histological parameters, including disease stage. In people with PBC, reactive ductules were associated with the establishment of junctions with bile canaliculi and with fibrogenetic cell activation. Consistently, in a mouse model of intrahepatic cholestasis, UDCA treatment was effective in reducing ductular reaction and fibrosis and increasing ductular-canalicular junctions. Conclusions: Extensive ductular reaction outlines a severe histologic phenotype in PBC and is associated with an inadequate therapy response and a worse estimated prognosis. Lay summary: In people affected by primary biliary cholangitis (PBC), the histological appearance of extensive ductular reaction identifies individuals at risk of progressive fibrosis. Ductular reaction at diagnosis correlates with the lack of response to first-line therapy with ursodeoxycholic acid and serves to restore ductular-canalicular junctions in people with PBC. Assessing ductular reaction extension at diagnosis may add valuable information for clinicians.
Background & Aims: Primary biliary cholangitis (PBC) is a chronic cholangiopathy characterised by immuno-mediated injury of interlobular bile ducts leading to intrahepatic cholestasis and progressive liver fibrosis. PBC histology is characterised by portal inflammation, progressive fibrosis, ductopenia, and the appearance of the so-called ductular reaction. The aim of the present study was to investigate the pathogenetic relevance of ductular reaction in PBC. Methods: Liver biopsies were collected from naïve people with PBC (N = 87). Clinical-serological parameters were obtained at diagnosis and after 1 year of ursodeoxycholic acid (UDCA) treatment. Histological staging was performed on all slides according to multiple scoring systems and criteria for PBC. Liver samples were obtained from Mdr2 -/- mice treated with or without UDCA. Samples were processed for histology, immunohistochemistry, and immunofluorescence. Results: Ductular reaction in people with PBC correlated with the disease stage and liver fibrosis, but not with disease activity; an extensive ductular reaction correlated with serum alkaline phosphatase levels at diagnosis, response to UDCA, and individuals' estimated survival, independently from other histological parameters, including disease stage. In people with PBC, reactive ductules were associated with the establishment of junctions with bile canaliculi and with fibrogenetic cell activation. Consistently, in a mouse model of intrahepatic cholestasis, UDCA treatment was effective in reducing ductular reaction and fibrosis and increasing ductular-canalicular junctions. Conclusions: Extensive ductular reaction outlines a severe histologic phenotype in PBC and is associated with an inadequate therapy response and a worse estimated prognosis. Lay summary: In people affected by primary biliary cholangitis (PBC), the histological appearance of extensive ductular reaction identifies individuals at risk of progressive fibrosis. Ductular reaction at diagnosis correlates with the lack of response to first-line therapy with ursodeoxycholic acid and serves to restore ductular-canalicular junctions in people with PBC. Assessing ductular reaction extension at diagnosis may add valuable information for clinicians.
Authors: Tania A Roskams; Neil D Theise; Charles Balabaud; Govind Bhagat; Prithi S Bhathal; Paulette Bioulac-Sage; Elizabeth M Brunt; James M Crawford; Heather A Crosby; Valeer Desmet; Milton J Finegold; Stephen A Geller; Annette S H Gouw; Prodromos Hytiroglou; A S Knisely; Masamichi Kojiro; Jay H Lefkowitch; Yasuni Nakanuma; John K Olynyk; Young Nyun Park; Bernard Portmann; Romil Saxena; Peter J Scheuer; Alastair J Strain; Swan N Thung; Ian R Wanless; A Brian West Journal: Hepatology Date: 2004-06 Impact factor: 17.425
Authors: Elisabeth M G de Vries; Manon de Krijger; Martti Färkkilä; Johanna Arola; Peter Schirmacher; Daniel Gotthardt; Benjamin Goeppert; Palak J Trivedi; Gideon M Hirschfield; Henriette Ytting; Ben Vainer; Henk R van Buuren; Katharina Biermann; Maren H Harms; Olivier Chazouilleres; Dominique Wendum; Astrid D Kemgang; Roger W Chapman; Lai Mun Wang; Kate D Williamson; Annette S H Gouw; Valerie Paradis; Christine Sempoux; Ulrich Beuers; Stefan G Hübscher; Joanne Verheij; Cyriel Y Ponsioen Journal: Hepatology Date: 2017-01-11 Impact factor: 17.425
Authors: Gideon M Hirschfield; Jessica K Dyson; Graeme J M Alexander; Michael H Chapman; Jane Collier; Stefan Hübscher; Imran Patanwala; Stephen P Pereira; Collette Thain; Douglas Thorburn; Dina Tiniakos; Martine Walmsley; George Webster; David E J Jones Journal: Gut Date: 2018-03-28 Impact factor: 23.059